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Introduction: Simplified Acute Physiology Score 3 (SAPS 3) was the first critical care prognostic model developed
from worldwide data. We aimed to systematically review studies that assessed the prognostic performance of SAPS
3 general and customized models for predicting hospital mortality in adult patients admitted to the ICU.
Methods: Medline, Lilacs, Scielo and Google Scholar were searched to identify studies which assessed calibration
and discrimination of general and customized SAPS 3 equations. Additionally, we decided to evaluate the correlation
between trial size (number of included patients) and the Hosmer-Lemeshow (H-L) statistics value of the SAPS 3 models.
Results: A total of 28 studies were included. Of these, 11 studies (42.8%) did not find statistically significant mis-calibration
for the SAPS 3 general equation. There was a positive correlation between number of included patients and higher H-L
statistics, that is, a statistically significant mis-calibration of the model (r = 0.747, P <0.001). Customized equations for major
geographic regions did not have statistically significant departures from perfect calibration in 9 of 19 studies. Five studies
(17.9%) developed a regional customization and in all of them this new model was not statistically different from a perfect
calibration for their populations. Discrimination was at least very good in 24 studies (85.7%).
Conclusions: Statistically significant departure from perfect calibration for the SAPS 3 general equation was common in
validation studies and was correlated with larger studies, as should be expected, since H-L statistics (both C and H) are
strongly dependent on sample size This finding was also present when major geographic customized equations were
evaluated. Local customizations, on the other hand, improved SAPS 3 calibration. Discrimination was almost always very
good or excellent, which gives excellent perspectives for local customization when a precise local estimate is needed.Introduction
Prognostic models are important tools in critical care
medicine [1]. They are used for mortality predictions and
for illness severity assessment in clinical trials. Acute
physiology and chronic health evaluation II (APACHE II)
[2] and simplified acute physiology score II (SAPS II) [3]
are the most commonly used models worldwide. Although
they are still able to assess severity in clinical trials, their
usefulness for mortality predictions has been questioned
due to a lack of prognostic performance over time, since
they were developed more than 20 years ago. This limita-
tion is very important because observed-to-expected
mortality ratios have become standard to assess the im-
pact of ICU factors on outcome and are among the* Correspondence: paulo_nassar@yahoo.com.br
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to evaluate quality of care [4].
In 2002, a worldwide group of researchers collected new
data about physiologic alterations, clinical presentation
and outcome of critically ill patients in more than 300
ICUs worldwide [5]. These data led to the development of
a new prognostic model, the SAPS III [6]. For the first
time, a general outcome prediction model included data
from outside Europe or the USA. Besides the general
equation for mortality estimation, SAPS III also provided
the end-user with customized equations for seven different
regions of the world, which would theoretically improve
care quality evaluations and benchmarking.
Since then, SAPS III models have been prospectively
evaluated for their performance in several regional studies.
Our aim was to systematically review studies that assessed
the prognostic performance of SAPS III general andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Medline, Lilacs (Literatura Latino-Americana e do Caribe
em Ciências da Saúde) and Scielo (Scientific Electronic
Library Online) were searched for articles published from
1 January 2005 (because the original SAPS III description
was published in that year) to 1 October 2013 using the
term ‘simplified acute physiology scoreʼ. Besides that,
Google Scholar was searched for articles that cited the
original SAPS III publication [6]. Titles and abstracts
returned by the search strategy were analyzed for eligibility
and full-text copies of articles deemed to be potentially rele-
vant were retrieved. Duplicate publications were excluded,
as well as studies published only as abstracts and editorials,
letters and narrative reviews. Only articles published in
English, Portuguese, Spanish or French were included.
Eligibility assessment was performed independently in
an unblinded standardized manner by two reviewers
(APNJ and LMSM). Disagreements were resolved by
consensus. The preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement was
used for guidance [7]. This study did not need ethical
approval nor was individual patient consent needed as
only data from published studies were used.
Study selection
One of the criteria used to include studies in this review
was whether they assessed the general SAPS III equation
performance on predicting hospital mortality in an adult
population (≥16 years-old) admitted to an ICU. Included
studies needed to have evaluated at least both calibration
and discrimination of the model. Calibration refers to
whether the predicted probabilities of death in the hospital
agree with the observed ones. Discrimination refers to the
ability of the model to distinguish high-risk subjects from
low-risk subjects. When reported in the included studies,
calibration and discrimination data from customized
SAPS III equations for major areas of the world were
also reported here.
We decided to include only studies that used data col-
lected after 2002, when data for original SAPS III were
available [5,6]. This decision was made in order to avoid
conclusions about performance of the model based on a
different profile of treatments administered in a previous
period of time.
Quality assessment
Included studies were evaluated for quality according to
the following items, based on a guideline for systematicreview of prognostic studies [8]: 1) study participation:
study population was clearly defined and described; 2)
prognostic factor measurement: SAPS III was properly
measured (that is, data were collected as described on
the original study); 3) analysis: adequate description of the
test methods for discrimination and calibration and suffi-
cient presentation of data to assess adequacy of analysis.
Data extraction
We developed a data extraction sheet. One author (APNJ)
extracted the following data from included studies: num-
ber of patients, mean or median age, percentage of female
patients and percentage of patients admitted for a surgical
reason (defined as ICU admission from the operating
room when not explicitly stated). The second author
(LMSM) checked the extracted data. Authors of the
included studies were contacted by email to complete
the missing data that were required for characterizing
the studies. When the authors could not be contacted,
did not reply or their answer was still unclear, empty
fields were marked ‘Not Reported (NR)’.
For each included study, we described the reported
calibration and discrimination. Calibration is usually mea-
sured by the Hosmer-Lemeshow (H-L) goodness-of-fit
H- or C-statistics. These statistics test for significant
departures from perfect calibration when P-values are
greater than 0.05. The H-statistic is based on fixed cut
points on the predictions (for example, deciles of risk)
whereas the C-statistic is based on equally sized groups,
based on probability of death. Additionally, calibration
may be evaluated by the Cox test of calibration. In this
case, logistic regression is used to verify the agreement
between predicted and observed risks.
In studies in which both the general and the customized
SAPS III showed significant departure from perfect cali-
bration, we assessed if authors performed a customization
and if this new model was an adequate calibration for the
study population. First-level customization is performed
using logistic regression analysis by computing a new
logistic coefficient while maintaining the same variables
with the same weights as the original model [9].
Discrimination is assessed measuring the area under
the receiver operator characteristic (aROC) curve. aROC
and its 95% CI were calculated. Discrimination was con-
sidered excellent, very good, good, moderate or poor
with aROC values of 0.9 to 0.99, 0.8 to 0.89, 0.7 to 0.79,
0.6 to 0.69 and ≤0.6, respectively. When available, we
also presented the standardized mortality ratio (SMR)
for hospital mortality reported in the studies. SMR is
calculated by dividing observed hospital mortality by the
predicted hospital mortality.
As classical calibration tests (such as H-L statistics) are
extremely sensitive to sample size [10,11], we decided to
evaluate if there was a correlation between sample size
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calculated between the number of included patients and
the value of H-L statistics found. For studies presenting
both the H- and C-statistic, we choose the one that
reported the lower value. Analysis was performed on
SPSS version 22.0 (SPSS Inc.).
Results
Study characteristics
Out of 923 studies initially identified, 31 full-text articles
were assessed for eligibility. Two were excluded for not
performing any measure of calibration [12,13] and one
for using data collected before 2002 [14]. Twenty-eight
studies were included in this analysis (Figure 1).
Table 1 shows the characteristics of the included studies.
According to major geographic regions defined in the
original SAPS III study, there were ten studies (35.7%)
performed in Central and South America [15-24], one
(3.6%) in North America [25], eight (34.8%) in Australasia
[26-33], three (10.7%) in Central and Western Europe
[34-36], two (7.1%) in Northern Europe [37,38] and four
(14.3%) in Southern Europe and Mediterranean countries
[39-42]. Most studies (53.5%) were performed in a single
ICU. Included studies examined the total number of
63,261 patients, ranging from 95 to 28,357.
Although most studies aimed to validate SAPS III on a
broad population in medical, surgical or mixed ICUs, nine
studies (32.1%) applied SAPS III to patients with specific
conditions such as cancer [15,20], elderly [17], acute kidney
injury (AKI) [18,21,31], acute coronary syndromes [23],
septic shock [30] and transplant patients [24].Figure 1 Search strategy. SAPS, simplified acute physiology score.Khwannimit et al. performed three studies in the same
ICU and enrolled some patients in more than one study
[27,28,30]. Lim et al. included 4,617 patients, but the
SAPS III general equation was only assessed on 2,309
patients, a ‘development cohortʼ in which a customized
Korean SAPS III was generated [33]. The Australasian
SAPS III equation was assessed in the entire population,
but we only extracted data from the development cohort
for comparison with SAPS III general equation data on
calibration and SMR.
Study quality
Study quality assessment is shown in Table 2. Three
studies did not calculate SAPS III with data collected
within one hour from admission. Tsai et al. aimed to
validate SAPS III at dialysis commencement in a popula-
tion supported by extracorporeal membrane oxygenation
[31]. Although they also calculated SAPS III at ICU
admission, they only evaluated discrimination at this
point. Maccariello et al. applied SAPS III in an AKI
population at the start of renal replacement therapy
[18]. Costa e Silva et al. also studied an AKI population
and applied SAPS III on AKI diagnosis and on nephrology
consultation day, using data collected during the previous
24 hours [21].
Calibration and discrimination
Only one study opted for the Cox calibration test instead of
H-L statistics to assess calibration [41]. A non-significant
departure from the perfect calibration was found in eleven
studies (42.8%) (Table 3) [15,16,18,19,21,29,31,32,37,38,40].
A positive correlation was found between sample size
and the value of H-L statistics in the 27 studies that used
it to assess calibration (r = 0.747; P <0.001), meaning that
larger studies correlated with higher H-L values represent-
ing greater power to detect mis-calibration.
Nineteen studies (67.9%) also assessed calibration for the
customized SAPS III equation for their major geographic
region (Table 3) [15,17,18,20,21,24,26,27,32-37,39-42].
A non-significant departure from perfect calibration was
found in six studies, in which the general equation also
did not show a statistically significant mis-calibration
[15,18,21,32,37,40]. Three studies [20,26,34], did not
show a significant departure from perfect calibration
for SAPS III customized equations, unlike the general
SAPS III equation, which was statistically significantly
mis-calibrated in those studies. In all remaining 10
studies, significant departures from perfect calibration
were found for both customized and general equations
[17,24,27,28,32,33,35,36,39,41,42].
Five studies (17.9%), in which both general SAPS III
equation and major geographic customized equations were
statistically significantly different from perfect calibration,
performed a regional customization. All studies developed
Table 1 Study characteristics
Study Setting Study period Number of
patients




Soares, 2006 [15] 1 ICU, Brazil Jan 2003 to Dec 2005 952 Mean: 58.3 45.3 63.5 33.5
Serrato, 2007 [16] 1 ICU, Mexico Jan 2006 to May 2006 95 Mean: 59 49.0 28.0 20.0
Ledoux, 2008 [34] 1 ICU, Belgium Dec 2005 to Jul 2006 802 Median: 66 39.4 71.1 17.5
Duke, 2008 [26] 1 ICU, Australia Oct 2005 to Dec 2007 1,741 Median: 66 47.4 39.4 11.3
Tsai, 2008 [31] 1 ICU, Taiwan Jan 2002 to Dec 2006 104 Mean: 51 42.3 61.4 76
Sakr, 2008 [35] 1 ICU, Germany Aug 2004 to Dec 2005 1,851 Mean: 61.6 36.6 85.8 9.0
Metnitz, 2009 [36] 22 ICU, Austria Oct 2006 to Feb 2007 2,060 Mean: 64.9 42.0 57.5 21.7
Capuzzo, 2009 [39] 2 ICU, Italy Jan 2006 to Sep 2007 684 Median: 73 37.0 81.8 19.6
Strand, 2009 [37] 2 ICU, Norway Jun 2006 to Dec 2007 1,862 Median: 63 36.0 29.4 23.6
Alves, 2009 [17] 1 ICU, Brazil Jan 2006 to Dec 2006 350 Mean: 73.4a 48.0 31.1 30.6
Mbongo, 2009 [40] 1 ICU, Spain Jan 2006 to Dec 2006 864 Mean: 60.7 34.7 86.3 8.2
Poole, 2009 [41] 147 ICU, Italy Feb 2007 to Dec 2007 28,357 Mean: 65.8 40.7 53.5 29.6
Median: 70
Maccariello, 2010 [18] 11 ICU, Brazil Jan 2007 to Jul 2008 244 Mean: 69.5 43.0 19.0 68.0
Silva Junior, 2010 [19] 2 ICU, Brazil Mar 2008 to Mar 2009 1,310 Mean: 67.1 60.5 100 10.8
Khwannimit, 2010 [27] 1 ICU, Thailand Jan 2005 to Dec 2010 1,873 Median: 62 41.1 0 28.6
Soares, 2010 [20] 28 ICU, Brazil Aug 2007 to Sep 2009 717 Mean: 61.2 51.0 64.0 30.0
Khwannimit, 2011 [28] 1 ICU, Thailand Mar 2007 to Aug 2009 2,022 Median: 62 40.0 0 26.1
Lim, 2011 [32] 1 ICU, South Korea Mar 2008 to Feb 2009 633 Mean: 60 37.0 0 31.0
Costa e Silva, 2011 [21] 6 ICU, Brazil Nov 2003 to Jun 2005 366 Mean: 57.1 41.0 23.5 67.8
Christensen, 2011 [38] 1 ICU, Denmark Jan 2007 to Dec 2007 469 NR 66.3 63.5 17.7
Juneja, 2012 [29] 1 ICU, India Jul 2008 to Sep 2009 653 Mean: 58.5 42.1 0 15.8
Nassar Junior, 2012 [22] 3 ICU, Brazil Jul 2008 to Dec 2009 5,780 Median: 66 52.7 20.9 9.1
Keegan, 2012 [25] 3 ICU, USA Jan 2006 to Dec 2006 2,596 Mean: 63.2 45.2 19.8 10.9
Nassar Junior, 2013 [23] 3 ICU, Brazil Jul 2008 to Dec 2009 1,015 Median: 61 40.4 0 2.1
De Oliveira, 2013 [24] 1 ICU, Brazil May 2006 to Jan 2007 501 Mean: 46 34.5 100 7.8
Khwannimit, 2013 [30] 1 ICU, Thailand Jan 2005 to Dec 2010 880 Median: 59 42.4 30.6 57.4
Lim, 2013 [33] 22 ICU, South Korea Jul 2010 to Jan 2011 2,309b Median: 62 35.3 39.8 20.1
López-Caler, 2013 [42] 6 ICU, Spain Jan 2006 to Oct 2007 2,171 Mean: 61.4 NR 37.2 16.0
aOnly patients aged ≥60 years were included; bdevelopment cohort in which a customized SAPS III equation was developed. NR, not reported.
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departure from perfect calibration for their populations
[27,28,33,35,36]. Only two of these studies were multicenter
[33,36].
Discrimination was always very good (aROC 0.80 to
0.89) or excellent (aROC ≥0.90) in 24 studies (85.7%)
[15-23,25-30,33-37,39-42]. None of the studies showed
poor discrimination (Table 3).
Mortality prediction
Twenty-five studies (89.3%) reported SMR for hospital
mortality [15-30,32-34,36,37,39-42]. The SAPS III general
equation underestimated hospital mortality in six studies
(24%) [15,18-21,24] and overestimated it in 15 (60%)
[22,23,25-29,33,34,36,37,39-42]. Two studies (8%) reportedan SMR lower than 1 but did not report the 95% CI [16,32]
(Table 3).
Out of the 19 studies that assessed the customized SAPS
III equation for their major geographic region, the cus-
tomized SAPS III still overestimated hospital mortality in
10 studies (52.6%) [27,28,32-34,36,37,39-41]. In one study,
the customized SAPS III also underestimated hospital
mortality [24]. However, in six studies, switching from the
general to the customized equation was associated with
better mortality estimation [15,18,20,21,26,34] (Table 3).
Discussion
This systematic review of literature identified 28 studies
that addressed SAPS III performance in external popula-
tions. As SAPS III enrolled patients from diverse countries,






Soares, 2006 [15] Yes Yes Yes
Serrato, 2007 [16] Yes Yes Yes
Ledoux, 2008 [34] Yes Yes Yes
Duke, 2008 [26] Yes Yes Yes
Tsai, 2008 [31] Yes No Yes
Sakr, 2008 [35] Yes Yes Yes
Metnitz, 2009 [36] Yes Yes Yes
Capuzzo, 2009 [39] Yes Yes Yes
Strand, 2009 [37] Yes Yes Yes
Alves, 2009 [17] Yes Yes Yes
Mbongo, 2009 [40] Yes Yes Yes
Poole, 2009 [41] Yes Yes Yes
Maccariello, 2010 [18] Yes No Yes
Silva Junior, 2010 [19] Yes Yes Yes
Khwannimit, 2010 [27] Yes Yes Yes
Soares, 2010 [20] Yes Yes Yes
Khwannimit, 2011 [28] Yes Yes Yes
Lim, 2011 [32] Yes Yes Yes
Costa e Silva, 2011 [21] Yes No Yes
Christensen, 2011 [38] Yes NR Yes
Juneja, 2012 [29] Yes Yes Yes
Nassar Junior, 2012 [22] Yes Yes Yes
Keegan, 2012 [25] Yes Yes Yes
Nassar Junior, 2013 [23] Yes Yes Yes
De Oliveira, 2013 [24] Yes Yes Yes
Khwannimit, 2013 [30] Yes Yes Yes
Lim, 2013 [33] Yes Yes Yes
López-Caler, 2013 [42] No Yes Yes
NR, not reported.
Nassar et al. Critical Care 2014, 18:R117 Page 5 of 9
http://ccforum.com/content/18/3/R117it would be reasonable to suppose it would perform
well in external validation studies. However, this was
not the rule. SAPS III general equations discriminated very
well in almost all studies, but calibration tests suggested
significant departures from perfect calibration in most of
them, especially in large studies (as should be expected by
the extensive use of the H-L, C- and H-statistics). SAPS III
customized equations have not delivered a better perform-
ance than the general equation in most of the studies.
However, local customization has provided non-statistically
significant departures from perfect calibration for SAPS III
in all studies that performed it.
Calibration refers to the agreement between observed
and predicted risks. A non-statistically significant depart-
ure from perfect calibration, that is, a P-value higher than
0.05, in an external validation study means the prognosticmodel predicts mortality risk adequately in this popula-
tion. Therefore, this population and the one in which
the original model was developed are similar. A series
of reasons can be responsible for significant departures
from perfect calibration. Among these are sampling
bias, variations in case-mix and temporal bias (either in
the process of care or in the case-mix).
SAPS III original cohort included patients with a median
age of 64 years; 39.4% of the patients were female and
51.5% of them were surgical (elective and emergency).
Differences in case-mix were important in the included
studies. Mean or median age varied from 46.0 to
73.4 years-old; female patients varied from 34.5 to
66.3%; and the proportion of surgical patients varied
from 0 to 100%. Interestingly, if we choose two studies
with similar populations according to these three vari-
ables - studies performed by Metnitz [36] and by Strand
[37] - we observe that a significant departure from perfect
calibration was found in the former, but not in the latter.
Even more interestingly, SAPS III had non-significant de-
partures from perfect calibration in studies that included
higher proportions of surgical patients [15,19,20,34] than
the original SAPS III study, but that also happened in a
study that included only medical patients [29]. Of course,
not only these three variables explain similar or different
case-mixes. Poor SAPS III performance may also be due
to differences in healthcare provisions [43] and end-of-life
policies [44], for example.
Another point that deserves attention is the application
of a prognostic model in a population admitted to ICU
because of a specific diagnosis. SAPS III had a non-
significant departure from perfect calibration and still
had very good discrimination in a common ICU syn-
drome - AKI - when calculated with data collected on
the diagnosis day, on the day of nephrology consultation
[21] or at the start of renal replacement therapy [18,31].
On the other hand, SAPS III was statistically significantly
mis-calibrated in an assessment of septic shock patients,
although it discriminated very well [30]. Two studies that
included patients with a specific diagnosis at admission,
however, showed very poor performance of SAPS III. In
transplant patients, SAPS III was statistically significantly
mis-calibrated, had only moderate discrimination and
underestimated hospital mortality [24]. In acute coronary
syndrome patients, SAPS III also was statistically signifi-
cantly mis-calibrated and overestimated hospital mortality,
although it discriminated well in this population [23]. These
findings are not unexpected. General prognostic models
usually do not perform well in specific subgroups of
patients because they may be under-represented in the de-
veloped cohort [6]. For some specific diagnoses, a specific
prognostic model may be an attractive alternative [23,45].
Temporal bias is another problem frequently reported as
a reason for significant differences from perfect calibration.





aROC (95% CI) SMR (95% CI) for
general SAPS III
SMR (95% CI) for
customized SAPS III
Central and South America
Soares, 2006 [15] C: 13.637 (P = 0.092) C: 9.132 (P = 0.331) 0.87 (0.85 to 0.90) 1.19 (1.04 to 1.37) 0.95 (0.84 to 1.07)
Serrato, 2007 [16] C: 6.64 (P >0.1) NR 0.86 (0.825 to 0.895) 0.81 NR
Alves, 2009 [17] H: 16.42 (P = 0.037) H: 16.66 (P = 0.034) 0.881 (0.843 to 0.913) 1.10 (0.90 to 1.33) 0.86 (0.70 to 1.04)
C: 17.57 (P = 0.025) C: 15.95 (P = 0.047)
Maccariello, 2010 [18] C: 10.16 (P = 0.254) C: 9.33 (P = 0.315) 0.82 (0.76 to 0.88) 1.26 (1.10 to 1.46) 1.04 (0.92 to 1.18)
Silva Junior, 2010 [19] C: 10.47 (P = 0.234) NR 0.86 (0.83 to 0.88) 1.04 (1.03 to 1.07) NR
Soares, 2010 [20] C: 15.804 (P = 0.045) C: 12.607 (P = 0.126) 0.84 (0.81 to 0.87) 1.29 (1.09 to 1.53) 1.02 (0.87 to 1.19)
Costa e Silva, 2011 [21] H (DD): 6.86 (P = 0.551) H (DD): 6.33 (P = 0.610) DD: 0.73 (0.67 to 0.78) DD: 1.35 (1.07 to 1.63) DD: 1.09 (0.83 to 1.35)
H (NCD): 10.47 (P= 0.163) H (NCD): 13.22 (P= 0.113) NCD: 0.80 (0.73 to 0.86) NCD: 1.15 (0.75 to 1.55) NCD: 1.00 (0.61 to 1.39)
Nassar Junior, 2012 [22] C: 226.6 (P <0.001) NR 0.855 (0.846 to 0.864) 0.46 (0.37 to 0.54) NR
Nassar Junior, 2013 [23] C: 51.8 (P <0.001) NR 0.804 (0.779 to 0.828) 0.31 (0.11 to 0.50) NR
De Oliveira, 2013 [24] H: 59.41 (P <0.001) C: 123.49 (P <0.001) 0.696 (0.607 to 0.786) 1.94 (1.38 to 2.64) 1.88 (1.34 to 2.56)
C: 155.57 (P <0.001) H: 45.6 (P <0.001)
North America
Keegan, 2012 [25] C: 36.6 (P <0.05) NR 0.801 (0.785 to 0.816) 0.66 (0.69 to 0.75) NR
Australasia
Duke, 2008 [26] H: 36.15 (P = 0.009) H: 27.37 (P = 0,06) 0.88 (0.85 to 0.90) 0.84 (0.724 to 0.969) 0.92 (0.80 to 1.06)
C: ? (P = 0.019)
Tsai, 2008 [31] H: 5.445 (P = 0.71) NR 0.73 NR NR
Khwannimit, 2010 [27] H: 106.7 (P <0.001) H: 98.2 (P <0.001) 0.933 (0.921 to 0.944) 0.86 (0.79 to 0.93) 0.92 (0.85 to 0.99)
C: 101.2 (P <0.001) C: 96.2 (P <0.001)
Khwannimit, 2011 [28] H: 101.6 (P <0.001) H: 79.9 (P <0.001) 0.916 (0.902 to 0.929) 0.81 (0.74 to 0.88) 0.88 (0.80 to 0.96)
C: 176.3 (P <0.001) C: 170 (P <0.001)
Lim, 2011 [32] C: 3.174 (P = 0.923) C: 3.286 (P = 0.915) 0.78 (0.75 to 0.81) 0.72 (0.62 to 0.83) 0.78 (0.67 to 0.89)
Juneja, 2012 [29] HL(?): 13.12 (P = 0.108) NR 0.901 (0.871 to 0.932) 0.763 (0.628 to 0.918) NR
Khwannimit, 2013 [30] H: 39.4 (P <0.001) NR 0.817 (0.790 to 0.845) 0.97 (0.89 to 1.06) NR
C: 49.6 (P <0.001)
Lim, 2013 [33] H: 123.06 (P <0.001) H: 73.53 (P <0.001) 0.829 (0.82 to 0.86) 0.72 (0.65 to 0.78) 0.78 (0.71 to 0.85)
C: 118.45 (P <0.001) C: 70.52 (P <0.001)
Central and Western Europe
Ledoux, 2008 [34] C: 16.59 (P = 0.035) C: 8.30 (P = 0.405) 0.85 (0.82 to 0.89) 0.82 (0.70 to 0.93) 0.96 (0.84 to 1.08)
Sakr, 2008 [35] H: 211.84 (P <0.001) H: 177.37 (P <0.001) 0.84 (0.81 to 0.88) NR NR
C: 208.49 (P <0.001) C: 126.79 (P <0.001)
Metnitz, 2009 [36] H: 100.18 (P <0.001) H: 51.56 (P <0.001) 0.82 0.79 (0.74 to 0.85) 0.86 (0.80 to 0.92)
C: 90.29 (P <0.001) C: 45.61 (P <0.001)
Northern Europe
Strand, 2009 [37] C: 17.40 (P = 0.066) C: 18.25 (P = 0.051) 0.81 (0.79 to 0.93) 0.71 (0.65 to 0.78) 0.74 (0.68 to 0.81)
Christensen, 2011 [38] HL(?): 9.23 (P = 0.51) NR 0.69 (0.63 to 0.75) NR NR
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Southern Europe and Mediterranean countries
Capuzzo, 2009 [39] H: 23.36 (P = 0.002) H: 25.73 (P = 0.001) 0.835 (0.794 to 0.876) 0.83 (0.77 to 0.89) 0.81 (0.75 to 0.87)
C: 22.47 (P = 0.004) C: 26.19 (P = 0.001)
Mbongo, 2009 [40] C: 8.57 (P = 0.38) C: 7.5 (P = 0.48) 0.917 (0.880 to 0.954) 0.71 (0.56 to 0.90) 0.69 (0.55 to 0.87)
Poole, 2009 [41] Ua: 2,035,9 (P <0.001) Ua: 1,929.2 (P <0.001) 0.855 (0.851 to 0.860) 0.73 (0.72 to 0.75) 0.73 (0.72 to 0.75)
López-Caler, 2013 [42] HL(?): 20.05 (P <0.05) 0.855 (0.851 to 0.860) 0.845 (0.821 to 0.869) 0.89 (0.80 to 0.98) 0.86 (0.77 to 0.95)
aROC, area under the receiver operator characteristic curve; SAP, simplified acute physiology score; SMR, standardized mortality ratios; H, Hosmer-Lemeshow
H-statistic; C, Hosmer-Lemeshow C-statistic; HL(?), Hosmer-Lemeshow statistic unspecified; NR, not reported; DD, acute kidney injury diagnosis-day; NCD, day of
nephrology consultation. aU statistics quantifies the difference from the null hypothesis, that is, a good fit of the model in the studied population when Cox
calibration test is used.
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changes in case-mix or clinical practice over time may limit
the application of a prognostic model. Analyzing study pe-
riods in Table 1 and calibrations in Table 3, it is not possible
to conclude that studies that collected data in a specific
period of time also found a better SAPS III performance.
A large database of patients from seven different major
geographic regions allowed SAPS III customized equations
for each region. In the original study, these customized
equations were not statistically significantly different from
perfect calibration [6]. Among included studies that also
assessed customized equations, there were only three in
which the customized equation did not show a statistically
significant mis-calibration in a population in which the
general equation also showed the same findings. Despite
being developed to fit better, these equations may not be
representative of populations from a specific region. For
example, SAPS III included 1,756 Australasian patients,
but these patients were only from Australia, Hong Kong
and India. Khwannimit et al. performed their studies in
a Thai population, and the Australasian SAPS III was
also statistically mis-calibrated [27,28,30]. Similar findings
were identified by Lim et al. in a broad South Korean
population [33].
A better explanation for SAPS III departures from per-
fect calibration may be the limitations of the statistics
methods used to evaluate performance. Calibration statis-
tics (specially H-L goodness-of-fit statistics) present several
problems, mainly the fact that they are very sensitive to
larger sample sizes because larger studies have more
power to detect departures from perfect calibration [10,46].
Thus, even small deviations from the perfect calibration in
larger studies may be associated with a P-value >0.05. An
interesting study compared the performance of SAPS II,
APACHE II and the mortality predict model II (MPM-II)
in a Dutch population of 42,139 patients. All models
showed statistically significant departures from perfect
calibration, both on the H-L and on the Cox calibration
test. However, when prognostic models were assessed
in subsamples drawn from the database, performance
was better. There was a tendency to reject the model
when these samples increased [11]. Our review suggesteda correlation between larger studies and higher values in
H-L statistics, as we should expect.
Although neither the SAPS III general equation nor its
customized equations for major geographic areas did not
show statistical goodness-of-fit in most studies, all studies
that performed a customization, developed local models
that did not show significant departures from perfect
calibration and had a very good discrimination. The devel-
opment of country-specific equations was previewed in the
original SAPS III description [6,36]. These findings high-
light the value and weight of variables included in SAPS III,
as first-line customizations provided valid models in all
studies. Models with only a few parameters, such as SAPS
III, are quite stable and can easily be turned into a statisti-
cally calibrated model with a first-level customization [47].
However, only two studies that developed local models
were multicenter. Thus, one may argue against considering
that a model is valid for a country or region if it was
customized only with data from a single ICU.
Discrimination refers to how well the model discrimi-
nates between an individual who will live and one who
will die. Good, very good or excellent discrimination was
found in almost all studies. Only two studies had an
aROC <0.7 [24,38]. Both were single center and one of
them was performed in transplant patients [24], a very
specific population. We believe this is a reassuring finding
for those using SAPS III for clinical or research purposes
in general populations of critically ill patients.
In addition to limitations of the included studies, one
possible limitation of this review is how databases were
searched. Although we did not restrict our search to
English language articles, there were language restrictions
that may have caused us to miss some studies. Also, we
performed searches on databases that include only studies
from Latin America (Lilacs), and from Latin America,
Portugal, Spain and South Africa (Scielo). That may have
been responsible for the high number of Latin American
and Spanish studies analyzed, which encompassed almost
half of the included studies. However, all studies, except
for two [16,17], were also indexed on Medline. One of
them was retrieved from Scielo [17] and the other from
Google Scholar [16].
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Although SAPS III was the first intensive care prognostic
model developed with patient data from different regions of
the world, its performance in external validation studies
was far from perfect. Even its major geographic customized
equations showed significant departures from perfect cali-
bration. Local and country customizations, on the other
hand, improved its performance. Discrimination was almost
always very good or excellent. We believe that SAPS III is a
reliable, simple and easy prognostic model to be used in
clinical practice, but it should be customized before routine
application in local settings. This statement is possibly
(probably) true for all general outcome prediction models.
In addition to that, it seems that SAPS III should not be
used to assess patients admitted with specific diagnoses.
Key messages
 SAPS III showed significant departure from perfect
calibration in most studies
 There was a positive correlation between larger
samples and higher H-L values for SAPS III. As
calibration statistics are very sensitive to sample
sizes, this is probably the best explanation for the
significant departures from perfect calibration found
in the larger studies
 SAPS III discrimination is very good
 First-level customization improved SAPS III
performance in all studies in which it was
accomplished, although most of them were
single-center studies
 SAPS III is a reliable prognostic model to be used in
clinical practice, but it should be customized before
routine application in local settings.
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